- December 13, 2022
Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury
- May 12, 2021
Perceptive Advisors Closes $515 Million Perceptive Xontogeny Venture Fund II, LP
- May 12, 2021
Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia
- May 12, 2021
Tellus Therapeutics Secures Seed Financing to Develop the First Treatment for Newborns with White Matter Brain Injury
- May 12, 2021
Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury
- May 12, 2021
NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease
- May 12, 2021
Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)
- December 10, 2019
Perceptive Advisors Closes Inaugural $210 Million Perceptive Xontogeny Venture Fund to Support Early-Stage Biotech Startups
- August 28, 2017
Xontogeny Appoints Industry Veteran Fred Callori as Senior Vice President of Corporate Development
- May 18, 2017
Xontogeny, a New Accelerator Operating Company, Launches with a $25 Million Series A Financing to Advance Early Stage Life Sciences Technology through Clinical Proof-of-Concept
